HK Stock MarketDetailed Quotes

02157 LEPU BIO-B

Watchlist

2.800
-0.180-6.04%

Trading Dec 23 11:16 CST

4.79BMarket Cap-59.57P/E (TTM)

LEPU BIO-B Key Stats

Cash Flow

All

YOY

Hide blank lines

(Q6)Jun 30, 2024

(FY)Dec 31, 2023

(Q6)Jun 30, 2023

(FY)Dec 31, 2022

(Q6)Jun 30, 2022

(FY)Dec 31, 2021

(FY)Dec 31, 2020

(FY)Dec 31, 2019

Turnover

-13.20%133.28M

1,347.16%225.35M

--153.55M

--15.57M

----

Operating income

-13.20%133.28M

1,347.16%225.35M

153.55M

15.57M

Cost of sales

-265.63%-21.04M

-1,310.32%-28.28M

---5.76M

---2.01M

----

Operating expenses

-265.63%-21.04M

-1,310.32%-28.28M

-5.76M

-2.01M

Gross profit

-24.06%112.24M

1,352.61%197.08M

147.8M

13.57M

Selling expenses

-216.05%-43.79M

-2,375.47%-43.3M

---13.86M

---1.75M

----

Administrative expenses

21.06%-30.84M

37.58%-86.66M

53.88%-39.07M

11.14%-138.83M

---84.73M

-66.64%-156.24M

51.05%-93.76M

---191.55M

Research and development expenses

6.58%-216.61M

12.63%-458.07M

-0.51%-231.87M

33.74%-524.29M

---230.71M

-123.24%-791.21M

-54.64%-354.43M

---229.2M

Revaluation surplus

-100.70%-124K

378.55%174.98M

129.18%17.74M

17.66%-62.82M

---60.78M

2.19%-76.29M

-103.57%-77.99M

---38.31M

-Changes in the fair value of financial assets

----

---60.78M

----

-103.57%-77.99M

---38.31M

-Changes in the fair value of other assets

-100.70%-124K

378.55%174.98M

--17.74M

17.66%-62.82M

----

---76.29M

----

Special items of operating profit

-486.61%-4.91M

2,192.30%220.77M

-76.98%1.27M

-31.68%9.63M

--5.52M

142.03%14.1M

32.21%5.82M

--4.41M

Operating profit

-55.97%-184.04M

100.68%4.8M

68.17%-118M

30.22%-704.48M

-370.7M

-94.03%-1.01B

-14.45%-520.35M

-454.66M

Financing income

-53.48%2.57M

-82.01%8.26M

-84.96%5.53M

1,008.35%45.92M

--36.75M

-21.92%4.14M

1,236.52%5.31M

--397K

Financing cost

-6.65%-8.47M

-85.23%-16.02M

-184.48%-7.94M

-52.21%-8.65M

---2.79M

93.42%-5.68M

-64.23%-86.32M

---52.56M

Special items of earning before tax

67.27%-7.04M

15.17%-27.34M

-84.67%-21.5M

-82.15%-32.23M

---11.64M

-46.43%-17.7M

-39.30%-12.08M

---8.68M

Earning before tax

-38.80%-196.97M

95.67%-30.3M

59.27%-141.9M

32.02%-699.44M

-348.37M

-67.72%-1.03B

-19.00%-613.45M

-515.49M

After-tax profit from continuing operations

-38.80%-196.97M

95.67%-30.3M

59.27%-141.9M

32.02%-699.44M

-348.37M

-67.72%-1.03B

-19.00%-613.45M

-515.49M

Earning after tax

-38.80%-196.97M

95.67%-30.3M

59.27%-141.9M

32.02%-699.44M

-348.37M

-67.72%-1.03B

-19.00%-613.45M

-515.49M

Minority profit

---4.54M

21.02%-8.21M

----

41.87%-10.39M

---4.09M

43.44%-17.87M

53.84%-31.6M

---68.46M

Profit attributable to shareholders

-35.61%-192.43M

96.79%-22.1M

58.78%-141.9M

31.84%-689.05M

-344.29M

-73.76%-1.01B

-30.16%-581.85M

-447.04M

Basic earnings per share

-33.33%-0.12

97.62%-0.01

57.14%-0.09

36.36%-0.42

-0.21

-29.41%-0.66

26.09%-0.51

-0.69

Diluted earnings per share

-33.33%-0.12

97.62%-0.01

57.14%-0.09

36.36%-0.42

-0.21

-29.41%-0.66

26.09%-0.51

-0.69

Currency Unit

CNY

Accounting Standards

IAS

Audit Opinions

Unqualified Opinion

Auditor

PricewaterhouseCoopers

	(Q6)Jun 30, 2024	(FY)Dec 31, 2023	(Q6)Jun 30, 2023	(FY)Dec 31, 2022	(Q6)Jun 30, 2022	(FY)Dec 31, 2021	(FY)Dec 31, 2020	(FY)Dec 31, 2019
Turnover	-13.20%133.28M	1,347.16%225.35M	--153.55M	--15.57M	----	----	----	----
Operating income	-13.20%133.28M	1,347.16%225.35M	153.55M	15.57M
Cost of sales	-265.63%-21.04M	-1,310.32%-28.28M	---5.76M	---2.01M	----	----	----	----
Operating expenses	-265.63%-21.04M	-1,310.32%-28.28M	-5.76M	-2.01M
Gross profit	-24.06%112.24M	1,352.61%197.08M	147.8M	13.57M
Selling expenses	-216.05%-43.79M	-2,375.47%-43.3M	---13.86M	---1.75M	----	----	----	----
Administrative expenses	21.06%-30.84M	37.58%-86.66M	53.88%-39.07M	11.14%-138.83M	---84.73M	-66.64%-156.24M	51.05%-93.76M	---191.55M
Research and development expenses	6.58%-216.61M	12.63%-458.07M	-0.51%-231.87M	33.74%-524.29M	---230.71M	-123.24%-791.21M	-54.64%-354.43M	---229.2M
Revaluation surplus	-100.70%-124K	378.55%174.98M	129.18%17.74M	17.66%-62.82M	---60.78M	2.19%-76.29M	-103.57%-77.99M	---38.31M
-Changes in the fair value of financial assets	----	----	----	----	---60.78M	----	-103.57%-77.99M	---38.31M
-Changes in the fair value of other assets	-100.70%-124K	378.55%174.98M	--17.74M	17.66%-62.82M	----	---76.29M	----	----
Special items of operating profit	-486.61%-4.91M	2,192.30%220.77M	-76.98%1.27M	-31.68%9.63M	--5.52M	142.03%14.1M	32.21%5.82M	--4.41M
Operating profit	-55.97%-184.04M	100.68%4.8M	68.17%-118M	30.22%-704.48M	-370.7M	-94.03%-1.01B	-14.45%-520.35M	-454.66M
Financing income	-53.48%2.57M	-82.01%8.26M	-84.96%5.53M	1,008.35%45.92M	--36.75M	-21.92%4.14M	1,236.52%5.31M	--397K
Financing cost	-6.65%-8.47M	-85.23%-16.02M	-184.48%-7.94M	-52.21%-8.65M	---2.79M	93.42%-5.68M	-64.23%-86.32M	---52.56M
Special items of earning before tax	67.27%-7.04M	15.17%-27.34M	-84.67%-21.5M	-82.15%-32.23M	---11.64M	-46.43%-17.7M	-39.30%-12.08M	---8.68M
Earning before tax	-38.80%-196.97M	95.67%-30.3M	59.27%-141.9M	32.02%-699.44M	-348.37M	-67.72%-1.03B	-19.00%-613.45M	-515.49M
After-tax profit from continuing operations	-38.80%-196.97M	95.67%-30.3M	59.27%-141.9M	32.02%-699.44M	-348.37M	-67.72%-1.03B	-19.00%-613.45M	-515.49M
Earning after tax	-38.80%-196.97M	95.67%-30.3M	59.27%-141.9M	32.02%-699.44M	-348.37M	-67.72%-1.03B	-19.00%-613.45M	-515.49M
Minority profit	---4.54M	21.02%-8.21M	----	41.87%-10.39M	---4.09M	43.44%-17.87M	53.84%-31.6M	---68.46M
Profit attributable to shareholders	-35.61%-192.43M	96.79%-22.1M	58.78%-141.9M	31.84%-689.05M	-344.29M	-73.76%-1.01B	-30.16%-581.85M	-447.04M
Basic earnings per share	-33.33%-0.12	97.62%-0.01	57.14%-0.09	36.36%-0.42	-0.21	-29.41%-0.66	26.09%-0.51	-0.69
Diluted earnings per share	-33.33%-0.12	97.62%-0.01	57.14%-0.09	36.36%-0.42	-0.21	-29.41%-0.66	26.09%-0.51	-0.69
Currency Unit	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY
Accounting Standards	IAS	IAS	IAS	IAS	IAS	IAS	IAS	IAS
Audit Opinions	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	Unqualified Opinion	Unqualified Opinion
Auditor	--	PricewaterhouseCoopers	--	PricewaterhouseCoopers	--	PricewaterhouseCoopers	PricewaterhouseCoopers	PricewaterhouseCoopers

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Heat List

Overall

No Data

Investment Theme

Pharmaceutical Companies

Intraday-1.18%

02157 LEPU BIO-B

LEPU BIO-B Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow